Valuation: Veru Inc.

Market Cap 49.11M 42.94M 39.46M 36.78M 69.76M 4.68B 70.82M 474M 184M 2.3B 184M 180M 7.92B P/E 2026 *
-3.01x
P/E 2027 * -3.11x
Enterprise Value 49.11M 42.94M 39.46M 36.78M 69.76M 4.68B 70.82M 474M 184M 2.3B 184M 180M 7.92B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.01%
Yield 2026 *
-
Yield 2027 * -
1 day-6.05%
1 week-12.31%
Current month-12.59%
1 month-8.80%
3 months+14.00%
6 months+17.42%
Current year+27.85%
1 week 2.7
Extreme 2.7001
3.35
1 month 2.7
Extreme 2.7001
3.43
Current year 2.05
Extreme 2.05
7.33
1 year 2.05
Extreme 2.05
7.33
3 years 2.05
Extreme 2.05
19.2
5 years 2.05
Extreme 2.05
245.5
10 years 2.05
Extreme 2.05
245.7
Manager TitleAgeSince
Chief Executive Officer 65 2016-10-30
Director of Finance/CFO 67 2012-12-31
Chief Tech/Sci/R&D Officer 64 2018-03-31
Director TitleAgeSince
Chairman 65 2018-02-28
Director/Board Member 68 2016-09-30
Director/Board Member 68 2018-02-28
Date Insider Type Main position Quantity % Market Cap.
05-03Free

Director

160,000 0.9969%
05-03Free

Director

100,000 0.6230%
05-03Free

Chief Financial Officer

164,000 1.0218%
Change 5-day change 1-year change 3-year change Capi.($)
-6.05%-12.31%-53.12%-75.35% 49.11M
-3.44%+2.19%+72.27%+128.14% 59.1B
+2.32%+5.03%+75.26%+92.31% 55.19B
-3.73%+0.65%-13.79%-10.30% 24.67B
-2.70%+4.49%+12.88%+440.98% 24.19B
+0.64%+7.14%+50.90%-1.05% 19.69B
-3.06%+5.94%+39.18%-29.87% 17.56B
0.00%+20.78%+186.15%+347.42% 16.22B
+4.91%+20.18%+48.55% - 14.84B
-1.84%+2.28%+25.71%+187.20% 14.04B
Average -1.23%+8.12%+44.40%+119.94% 24.55B
Weighted average by Cap. -0.86%+6.47%+57.77%+133.49%

Financials

2026 *2027 *
Net sales - -
Net income -25.1M -21.94M -20.17M -18.8M -35.65M -2.39B -36.19M -242M -94.11M -1.17B -94.22M -92.19M -4.05B -37.1M -32.43M -29.81M -27.78M -52.7M -3.53B -53.49M -358M -139M -1.74B -139M -136M -5.98B
Net Debt - -
Logo Veru Inc.
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Employees
20
Date Price Change Volume
26-07-06 US$2.759 -9.84% 121,260
26-07-02 US$3.060 -3.16% 262,276
26-07-01 US$3.160 +0.96% 337,597
26-06-30 US$3.130 +0.32% 285,438
26-06-29 US$3.120 +3.65% 432,577
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.060USD
Average target price
24.50USD
Spread / Average Target
+700.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VERU Stock